John Araujo

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. doi request reprint Targeting Src signaling in metastatic bone disease
    John Araujo
    MD Anderson Cancer Center, Houston, TX 77030 3721, USA
    Int J Cancer 124:1-6. 2009
  2. pmc Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel
    John C Araujo
    Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer Manag Res 6:25-30. 2013
  3. doi request reprint Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial
    John C Araujo
    Department of Genitourinary Medical Onology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Electronic address
    Lancet Oncol 14:1307-16. 2013
  4. ncbi request reprint Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation
    John C Araujo
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer Biol Ther 8:2153-9. 2009
  5. ncbi request reprint Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors
    John Araujo
    Genitourinary Center, M D Anderson Cancer Centre, Houston, TX 77030, USA
    Cancer Treat Rev 36:492-500. 2010
  6. doi request reprint Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study
    John C Araujo
    The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:63-71. 2012

Detail Information

Publications6

  1. doi request reprint Targeting Src signaling in metastatic bone disease
    John Araujo
    MD Anderson Cancer Center, Houston, TX 77030 3721, USA
    Int J Cancer 124:1-6. 2009
    ..Because of the role of Src in both cancer development and in bone metabolism, it may provide a therapeutic target for patients with bone metastases...
  2. pmc Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel
    John C Araujo
    Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer Manag Res 6:25-30. 2013
    ..This brief report discusses in detail follow-up data on two patients who remain alive after >2.5 years on dasatinib single-agent therapy after discontinuing docetaxel treatment...
  3. doi request reprint Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial
    John C Araujo
    Department of Genitourinary Medical Onology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Electronic address
    Lancet Oncol 14:1307-16. 2013
    ..We assessed whether dasatinib plus docetaxel in chemotherapy-naive men with metastatic castration-resistant prostate cancer led to greater efficacy than with docetaxel alone...
  4. ncbi request reprint Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation
    John C Araujo
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer Biol Ther 8:2153-9. 2009
    ..Since Src kinase has been shown to be necessary for osteoclast function, we hypothesized that dasatinib, a Src family kinase inhibitor, would reduce osteoclast activity and prostate cancer (PC-3) cell-induced osteoclast formation...
  5. ncbi request reprint Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors
    John Araujo
    Genitourinary Center, M D Anderson Cancer Centre, Houston, TX 77030, USA
    Cancer Treat Rev 36:492-500. 2010
    ..Future clinical trials will further assess the clinical value of SRC inhibition with dasatinib...
  6. doi request reprint Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study
    John C Araujo
    The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:63-71. 2012
    ....